Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.

[1]  S. Yusuf,et al.  Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.

[2]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[3]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[4]  M. Sabatine,et al.  Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. , 2005, American heart journal.

[5]  P. Gurbel,et al.  The platelet-related effects of tenecteplase versus alteplase versus reteplase , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  F. Fernández‐Avilés,et al.  Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial , 2004, The Lancet.

[7]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. , 2004, The American journal of cardiology.

[8]  P. Théroux,et al.  Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. , 2004, Journal of the American College of Cardiology.

[9]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. , 2004, The American journal of cardiology.

[10]  U. Zeymer,et al.  Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty and Medical Therapy in Stable Survivors of Acute Myocardial Infarction With Single Vessel Disease: A Study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte , 2003, Circulation.

[11]  E. Antman,et al.  Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. , 2003, Journal of the American College of Cardiology.

[12]  F. Van de Werf,et al.  Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. , 2003, American heart journal.

[13]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[14]  E. Topol,et al.  Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword? , 2002, Circulation.

[15]  E. Braunwald,et al.  Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction , 2002, Circulation.

[16]  E. Antman,et al.  Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). , 2001, The American journal of cardiology.

[17]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[18]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[19]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[20]  C. Gibson,et al.  Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting , 1999, Annals of Internal Medicine.

[21]  P. Gurbel,et al.  Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  E. Topol,et al.  Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[23]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[24]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[25]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[26]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[27]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[28]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[29]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[30]  R. Gabriel.  IgA DEFICIENCY, HYPERTENSION, AND MULTICYSTIC RENAL DISEASE , 1976, The Lancet.